Xalud Therapeutics, Inc.

Xalud Therapeutics, Inc. is a biotechnology company founded in 2009 and based in the United States. The company's slogan reflects its mission "We seek to address the significant unmet need for safe and efficient treatments for chronic pain-related diseases." Xalud Therapeutics is focused on developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is leveraging the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to address pathologic inflammation and pain. The latest milestone for Xalud Therapeutics was a Series C investment of $30.00M led by PBM Capital on 24 August 2021. The company operates within the Biotechnology and Health Care industries, aiming to meet the unmet need for effective chronic pain treatments. Xalud's innovative approach to leveraging gene therapy to address inflammation presents a promising opportunity for potential investors looking to support advancements in biotechnology and healthcare.